Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, October 31, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Bristol-Myers Squibb Co. (NYSE: BMY), UnitedHealth Group Inc. (NYSE: UNH), Sanofi SA (NYSE: SNY) and Actavis plc (NYSE: ACT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7593-100free.

--
Celgene Corporation Research Reports
On October 23, 2014, Celgene Corporation (Celgene) reported that its Q3 2014 total revenue improved 18.4% YoY to $2.0 billion. The Company's Q3 2014 REVLIMID® sales were $1.3 billion, up 19.3% YoY, driven by volume in both the U.S. and International markets as a result of increased duration of therapy and continued market share leadership in multiple myeloma. The Company's Q3 2014 net income stood at $508.5 million or $0.61 per diluted share, compared to net income of $372.5 million or $0.43 per diluted share in Q3 2013. The Company posted 9M 2014 total revenue of $5.6 billion, up 17.9% YoY, and 9M 2014 net income improved 12.2% YoY to $1.4 billion. For full-year 2014, Celgene anticipates - total revenue to exceed $7.6 billion, an increase of approximately 17% YoY; REVLIMID® net product sales to slightly exceed $5.0 billion, up approximately 16%; and GAAP diluted EPS to be in the range of $2.38 - $2.48. The full research reports on Celgene are available to download free of charge at:

http://www.analystsreview.com/Oct-31-2014/CELG/report.pdf

--
Bristol-Myers Squibb Co. Research Reports
On October 24, 2014, Bristol-Myers Squibb Co. (Bristol-Myers) reported its Q3 2014 and 9M 2014 earnings. The Company reported Q3 2014 total revenues of $3.9 billion, down 3.5% YoY that includes 6.0% YoY decline in net product sales at $2.8 billion, which was partly offset by 3.7% YoY improvement in Alliance and other revenues at $1.1 billion. The Company posted Q3 2014 net earnings attributable to Bristol-Myers of $721 million, compared to $692 million in Q3 2013. The Company's Q3 2014 non-GAAP diluted EPS stood at $0.45. On average, 18 analysts polled by Thomson Reuters expected the Company to report Q3 2014 EPS (excluding special items) of $0.42 on revenues of $3.8 billion. The Company's 9M 2014 total revenues declined 2.7% YoY to $11.6 billion, while net earnings attributable to Bristol-Myers improved 8.4% YoY to $2.0 billion. For full-year 2014, the Company expects worldwide revenues between $15.2 billion and $15.8 billion and GAAP EPS in the range of $1.15 - $1.25. The full research reports on Bristol-Myers are available to download free of charge at:

http://www.analystsreview.com/Oct-31-2014/BMY/report.pdf

--
UnitedHealth Group Inc. Research Reports
On October 28, 2014, UnitedHealth Group Inc.'s indirect subsidiary - Optum announced that it has entered into a definitive agreement with Alere to acquire Alere Health and its subsidiaries, in a cash transaction worth $600 million. Optum informed that Alere provides leading condition management, case management, wellbeing, wellness and women's and children's health services. Optum further informed that Alere Health's health management capabilities will broaden and strengthen the value Optum provides to health care payers, employers and states by improving the health of the people they serve and reducing overall health care costs. Larry Renfro, CEO of Optum, said, "Adding Alere Health's solutions and expertise allow us to be an even more valuable partner to payers, employers, federal and state governments and consumers in achieving their long-term population health and cost management goals." The full research reports on UnitedHealth are available to download free of charge at:

http://www.analystsreview.com/Oct-31-2014/UNH/report.pdf

--
Sanofi SA Research Reports
On October 28, 2014, Sanofi SA (Sanofi) posted Q3 2014 net sales of €8.8 billion, up 4.1% YoY, reflecting sales growth in Pharmaceuticals segment (up 2.1% YoY), Vaccines segment (up 11.6% YoY) and Animal Health segment (up 12.4% YoY). During the quarter, the Company's Growth Platforms improved 10.0% at constant exchange rates (CER) to €6.9 billion, driven by the improved performance of Genzyme (up 24.6% CER), Vaccines (up 11.2% CER), Animal Health (up 12.7% CER) and Other Innovative Products (up 18.0% CER). The Company's Q3 2014 net income attributable to equity holders of Sanofi stood at €1.19 billion or €0.91 per share, compared to net income of €1.22 billion or €0.92 per share in Q3 2013. The Company's 9M 2014 net sales improved 0.8% YoY to €24.7 billion, while net income attributable to equity holders of Sanofi improved 14.9% YoY to €3.1 billion. The full research reports on Sanofi are available to download free of charge at:

http://www.analystsreview.com/Oct-31-2014/SNY/report.pdf

--
Actavis plc Research Reports
On October 23, 2014, Actavis plc (Actavis) reported that U.S. Court of Appeals for the Federal Circuit has upheld a lower court ruling that found U.S. Patent No. 7,704,984 to be valid and infringed by Lupin Pharmaceuticals, Inc. (Lupin) and Amneal Pharmaceuticals' (Amneal) Abbreviated New Drug Applications (ANDAs) for generic versions of Actavis' Lo Loestrin® Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets). As a result of the Court's ruling, Lupin and Amneal cannot launch their generic versions of Lo Loestrin Fe® until after the '984 Patent expires on February 2, 2029. The full research reports on Actavis are available to download free of charge at:

http://www.analystsreview.com/Oct-31-2014/ACT/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts Review

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.